Page History

Cancer Synoptic Reporting Project Group

07 March 2022 at 17:30 UTC

Item	Description	Owner	Notes	Action
1	Treatment effect	Scott Campbell	Continue discussion: What are we measuring when assessing "treatment effect"? Is this a histologic change? Viability of tumor cells? Primary site Lymph node Note: SSA wonders about property in this model	Primary site Lymph node Will review model. This observable pertains to the process of regression/change in the neoplasm after antineoplastic therapy. So, observable could be modeled as presence of process changes. Still a discussion. What is being measured? (Degree of presence of tumor). Can this be reproduced...base question is tumor there or not s/p therapy...tumor gone is best...everything else is questionable for the patient
2	Patterns	Scott Campbell	How to handle patterns within histologies Lung (Lepidic, acinar) DCIS Bladder (differentiation)	We can use the morphologic descriptors...maybe...TBD
3	Lymph nodes	Scott Campbell Stefan Dubois	Discuss approach to lymph node body structures and differences in naming/locations (example AJCC esophageal cancer vs. JES esophageal cancer) 2. Management of observables for lymph node involvement. Example:
4	AJCC update?	Jim Case	Any updates that can be shared?	Jim Case meeting with AJCC on Wednesday 26-Jan to continue/finalize contract issues

Attachments

Content Report Table